Merck: starts trial in diabetic retinopathy

(CercleFinance.com) - On Wednesday, Merck announced the start, in collaboration with its subsidiary EyeBio, of a phase 2b/3 trial dedicated to an experimental treatment for diabetic retinopathy.


As part of the clinical trial, the biopharmaceutical group plans to evaluate the efficacy of the Restoret antibody (MK-3000) in the treatment of this complication of diabetes.

Merck points out that MK-3000 showed encouraging results in the treatment of retinal diseases in a phase 1/2 study.

Merck has also announced that, at the annual congress of the European Society for Medical Oncology (ESMO) to be held in Barcelona from 13 to 17 September, it plans to unveil data on four approved drugs and six candidates in the treatment of some twenty cancers.


Copyright (c) 2024 CercleFinance.com. All rights reserved.